Endocrinology

Astellas Pharma's mirabegron (Mybetriq) will serve as a combination therapy with muscarinic antagonist solifenacin succinate (VESIcare) for the treatment of overactive bladder in patients with particular symptoms.

The new diabetes tech in question is the expanding pool of continuous glucose monitoring systems. So, what's your CGM IQ?

Despite extended exposure to high doses of estrogen therapy, levels of prolactin did not rise in transgender patients.

Medication adherence rates struggle in many conditions and diabetes is among the worst of them. Michael Greenfield, MD, discusses 3 ways for clinicians to improve adherence.

The investigational drug programs represent a high unmet medical need as there are currently no approved therapeutics targeting the impairment caused by the mutations.

New diabetes studies find SGLT2i may reduce all-cause mortality; that telemedicine can improve T2DM care; and that broader screening criteria are better.

Data from the 2 clinical trials showed that JYNARQUE slowed kidney function decline in adults at risk of rapidly progressing ADPKD.

The study showed that 21% of the girls with T2D also had menstrual dysfunction suggestive of polycystic ovarian syndrome.

A result of cooperation between Amerigen Pharmaceuticals and Dipharma, this is the first approved generic equivalent to Actelion Pharmaceuticals’ version of the drug, Zavesca.

Primary hyperparathyroidism--asymptomatic but curable. Here are three clinical pearls to help guide diagnosis and management.

A group of researchers is planning an ambitious project that could have implications for diseases like diabetes: to build a complete model of the pancreatic ß cell.

An analysis of 40-plus trials report that the closed loop system care can be the difference in 2.5 extra hours of daily normoglycemia.

The disparity of fast food swamps significantly affecting pediatric patients with T1D but not those with T2D came as a surprise to researchers.

SGLT-2 inhibitors and GLP-1 agonists were associated with 1% and 0.6% reductions in all-cause mortality, respectively.

The benefit for patients without diabetes was +0.3 ml/min/1.73 m2 per year and for those with concurrent diabetes, the benefit was doubled to +.06 ml/min/1.73 m2.

Results indicated that canagliflozin provided renal benefits for T2D patients with preserved or reduced kidney function.

The Phase 2 CARDINAL study is evaluating bardoxolone methyl (bardoxolone) in patients with chronic kidney disease because of Alport syndrome.

While conventional methods require some type of skin prick, scientists from the University of Bath have proven the concept of needleless CGM.

André the Giant, examines the life and work history of the WWE Hall of Famer. Unbeknownst to many, his size was the result of gigantism, a disease caused by excess growth hormone. The condition led to his eventual diagnosis with acromegaly, a rare endocrine disorder.

Women with PCOS face increased risk of psychiatric morbidity and their children are more likely to be diagnosed with ADHD or autism.

When taken early in a pregnancy, mifepristone can end a pregnancy that is less than 49 days along. Another notable trait of the drug, though, is its ability to control the high blood sugar in patients with Cushing syndrome who have type 2 diabetes and have either failed surgery or are not candidates for it.

New data has elucidated a mechanism of action by which hormonal replacement therapy could help prevent T2D in women after menopause.

Researchers note that efforts are needed to align clinical practice with clinical guidelines.

Study results showed significant HbA1c reduction when Bydureon was added to insulin glargine therapy versus insulin glargine alone.

The Beyond Type 1 Science Advisory Council member explains the warning signs of diabetes.